Get the Stockscreener App
32.03
1.10%
0.35
After Hours:
32.25
0.22
+0.69%
Genmab Adr stock is traded at $32.03, with a volume of 997.32K.
It is up +1.10% in the last 24 hours and up +11.37% over the past month.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
See More
Previous Close:
$31.68
Open:
$32.04
24h Volume:
997.32K
Relative Volume:
0.48
Market Cap:
$19.73B
Revenue:
$2.62B
Net Income/Loss:
$966.70M
P/E Ratio:
21.35
EPS:
1.5004
Net Cash Flow:
$1.09B
1W Performance:
+0.34%
1M Performance:
+11.37%
6M Performance:
+47.06%
1Y Performance:
+47.94%
1-Day Range:
$31.63
$32.41
1-Week Range:
$31.32
$32.48
52-Week Range:
$17.23
$33.65
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
32.03 | 19.51B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-01-25 | Downgrade | Bernstein | Mkt Perform → Underperform |
| Mar-11-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-13-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-20-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-15-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-23-24 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-22-24 | Downgrade | Citigroup | Neutral → Sell |
| Dec-06-23 | Upgrade | UBS | Neutral → Buy |
| Nov-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-08-23 | Upgrade | DNB Markets | Sell → Buy |
| Oct-18-23 | Initiated | Exane BNP Paribas | Underperform |
| Sep-06-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-24-23 | Initiated | BTIG Research | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-31-23 | Initiated | UBS | Neutral |
| May-12-23 | Initiated | Morgan Stanley | Underweight |
| Dec-20-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-14-22 | Initiated | William Blair | Mkt Perform |
| Nov-11-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-24-22 | Initiated | BMO Capital Markets | Market Perform |
| May-02-22 | Initiated | Cowen | Market Perform |
| Mar-16-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-01-21 | Initiated | Berenberg | Sell |
| Sep-16-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-24-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
| Jan-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-20 | Downgrade | Bryan Garnier | Neutral → Sell |
| Sep-08-20 | Initiated | SVB Leerink | Mkt Perform |
| Jun-25-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-23-20 | Initiated | Credit Suisse | Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Sep-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | Morgan Stanley | Overweight |
| Aug-12-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Genmab Adr Stock (GMAB) Latest News
How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter - Investor's Business Daily
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes - GlobeNewswire Inc.
Arbor Realty Trust Inc (ABR): What is the Risk Factor? - fostersleader.com
Genmab A/S Sponsored ADR $GMAB Shares Purchased by Creative Planning - Defense World
AlphaCore Capital LLC Invests $44,000 in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab ADR Earns Membership In 95-Plus Composite Rating Club - MSN
AIMZ Investment Advisors LLC Has $3.43 Million Position in Genmab A/S Sponsored ADR $GMAB - Defense World
Stocks To Watch: Immunocore Holdings ADR Sees RS Rating Rise To 83 - MSN
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Q1 Earnings Estimate for Genmab A/S Issued By HC Wainwright - Defense World
Ocular Therapeutix Stock Earns 81 RS Rating - Investor's Business Daily
FY2025 EPS Estimates for Genmab A/S Raised by HC Wainwright - Defense World
Syndax Pharmaceuticals Stock Earns RS Rating Upgrade - Investor's Business Daily
Leerink Partnrs Forecasts Weaker Earnings for Genmab A/S - Defense World
Stocks With Rising Relative Strength: Immunocore Holdings ADR - Investor's Business Daily
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
FY2025 EPS Estimates for Genmab A/S Raised by William Blair - Defense World
Genmab A/S Sponsored ADR $GMAB Position Reduced by Y Intercept Hong Kong Ltd - Defense World
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment - MSN
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S Sponsored ADR $GMAB Shares Sold by Ingalls & Snyder LLC - MarketBeat
William Blair Predicts Genmab A/S FY2027 Earnings - Defense World
Short Interest in Genmab A/S Sponsored ADR (NASDAQ:GMAB) Increases By 59.3% - MarketBeat
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Vanguard Personalized Indexing Management LLC Has $1.09 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
HC Wainwright Has Pessimistic View of Genmab A/S Q2 Earnings - Defense World
Genmab A/S’s (GMAB) “Buy” Rating Reiterated at HC Wainwright - Defense World
Truist Financial Corp Reduces Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Genmab A/S FY2026 EPS Estimate Reduced by Leerink Partnrs - Defense World
GMAB or TECH: Which Is the Better Value Stock Right Now? - MSN
Q3 EPS Estimates for Genmab A/S Lowered by Leerink Partnrs - MarketBeat
31,681 Shares in Genmab A/S Sponsored ADR $GMAB Purchased by Callan Family Office LLC - MarketBeat
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S Sponsored ADR $GMAB Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
William Blair Brokers Lift Earnings Estimates for Genmab A/S - MarketBeat
DAVENPORT & Co LLC Grows Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Wealth Enhancement Advisory Services LLC Buys New Shares in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab Adr Stock (GMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):